Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q6P1J9: Variant p.Leu64Pro

Parafibromin
Gene: CDC73
Feedback?
Variant information Variant position: help 64 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Leucine (L) to Proline (P) at position 64 (L64P, p.Leu64Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HRPT1; does not affect interaction with the Pfa1 complex. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 64 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 531 The length of the canonical sequence.
Location on the sequence: help GTGKEGQPREYYTLDSILFL L NNVHLSHPVYVRRAATENIP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GTGKEGQPREY--------YTLDSILFLLNNVHLSHPVYVRRAATENIP

Mouse                         GTGKEGQPREY--------YTLDSILFLLNNVHLSHPVYVR

Rat                           GTGKEGQPREY--------YTLDSILFLLNNVHLSHPVYVR

Chicken                       GTGKEGQPREY--------YTLDSILFLLNNVHLSHPVYVR

Caenorhabditis elegans        -----GKSDEF--------YSLESLVVFLKYSHENHGVYVK

Baker's yeast                 EETEIEIDGSL--------VQLRIIVHCWMNKDSSAADYLA

Fission yeast                 -----DEPTKFIKLENDSHFSLRSVYFAWLLRDTSIAEYIQ
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 531 Parafibromin
Helix 57 – 65



Literature citations
The parafibromin tumor suppressor protein is part of a human Paf1 complex.
Rozenblatt-Rosen O.; Hughes C.M.; Nannepaga S.J.; Shanmugam K.S.; Copeland T.D.; Guszczynski T.; Resau J.H.; Meyerson M.;
Mol. Cell. Biol. 25:612-620(2005)
Cited for: FUNCTION; INTERACTION WITH PAF1; LEO1 AND POLR2A; INTERACTION WITH SET1-LIKE COMPLEX; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANT HRPT1 PRO-64; HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.
Carpten J.D.; Robbins C.M.; Villablanca A.; Forsberg L.; Presciuttini S.; Bailey-Wilson J.; Simonds W.F.; Gillanders E.M.; Kennedy A.M.; Chen J.D.; Agarwal S.K.; Sood R.; Jones M.P.; Moses T.Y.; Haven C.; Petillo D.; Leotlela P.D.; Harding B.; Cameron D.; Pannett A.A.; Hoeoeg A.; Heath H. III; James-Newton L.A.; Robinson B.; Zarbo R.J.; Cavaco B.M.; Wassif W.; Perrier N.D.; Rosen I.B.; Kristoffersson U.; Turnpenny P.D.; Farnebo L.-O.; Besser G.M.; Jackson C.E.; Morreau H.; Trent J.M.; Thakker R.V.; Marx S.J.; Teh B.T.; Larsson C.; Hobbs M.R.;
Nat. Genet. 32:676-680(2002)
Cited for: INVOLVEMENT IN HRPT2; INVOLVEMENT IN HRPT1; VARIANT HRPT1 PRO-64; HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours.
Howell V.M.; Haven C.J.; Kahnoski K.; Khoo S.K.; Petillo D.; Chen J.; Fleuren G.J.; Robinson B.G.; Delbridge L.W.; Philips J.; Nelson A.E.; Krause U.; Hammje K.; Dralle H.; Hoang-Vu C.; Gimm O.; Marsh D.J.; Morreau H.; Teh B.T.;
J. Med. Genet. 40:657-663(2003)
Cited for: VARIANT HRPT1 PRO-64;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.